Repeated successful use of eltrombopag in chronic primary immune thrombocytopenia: description of an intriguing case | Zendy

Santoro Cristina | Zendy; Volpicelli Paola | Zendy; Baldacci Erminia | Zendy; Ferrara Grazia | Zendy; Di Rocco Alice | Zendy; Ferretti Antonietta | Zendy; Porrazzo Marika | Zendy; Mazzucconi Maria Gabriella | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Repeated successful use of eltrombopag in chronic primary immune thrombocytopenia: description of an intriguing case

Author(s) -

Santoro Cristina,

Volpicelli Paola,

Baldacci Erminia,

Ferrara Grazia,

Di Rocco Alice,

Ferretti Antonietta,

Porrazzo Marika,

Mazzucconi Maria Gabriella

Publication year - 2017

Publication title -

clinical case reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.21

H-Index - 9

ISSN - 2050-0904

DOI - 10.1002/ccr3.920

Subject(s) - eltrombopag , medicine , thrombopoietin , immune thrombocytopenia , romiplostim , thrombopoietin receptor , platelet , immunology , haematopoiesis , genetics , stem cell , biology

Key Clinical Message Thrombopoietin receptor agonists ( TPO ‐ RA s) are used as effective alternative treatments in ITP patients unresponsive to first‐/second‐line therapies. TPO ‐ RA s can also be used to normalize platelet count to safely perform invasive procedures and chemotherapy, in case of malignancies. In few responsive patients, TPO ‐ RA s can be suspended maintaining a sustained response.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research